Detailansicht

Wissensnetz

Person

Klaus F. Rabe

Arzt

Name	Klaus F. Rabe
Ort	Kiel (Wirkungsort) Deutschland
Geschlecht	männlich
Akademischer Grad bzw. Titel	Prof. Dr. med.
Beruf	Arzt (charakteristischer Beruf)
Variante	Klaus Rabe K. F. Rabe Klaus Friedrich Rabe
Weitere Angaben	Translational Lung Research Center Heidelberg; 2017- Präsident der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e. V. (DGP)
Datensatztyp	Person
GND-Nummer	142581453
Datensatz-ID	142581453
Beteiligt an alle anzeigen Effects of triple therapy on disease burden in patients of GOLD groups C and D: results from the observational COPD cohort COSYCONET S2k-Leitlinie zur fachärztlichen Diagnostik und Therapie von Asthma 2023 : herausgegeben von der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e. V. Risk Assessment for Patients with Chronic Respiratory Conditions in the Context of the SARS-CoV-2 Pandemic Statement of the German Respiratory Society with the Support of the German Association of Chest Physicians Risk Assessment for Patients with Chronic Respiratory Conditions in the Context of the SARS-CoV-2 Pandemic Statement of the German Respiratory Society with the Support of the German Association of Chest Physicians Correction to: Key summary of German national treatment guidance for hospitalized COVID‑19 patients : Key pharmacologic recommendations from a national German living guideline using an Evidence to Decision Framework (last updated 17.05.2021) Key summary of German national treatment guidance for hospitalized COVID-19 patients : Key pharmacologic recommendations from a national German living guideline using an Evidence to Decision Framework (last updated 17.05.2021) Risikoabschätzung bei Patienten mit chronischen Atemwegs- und Lungenerkrankungen im Rahmen der SARS-CoV-2-Pandemie : Stellungnahme der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e. V. (DGP) mit Unterstützung des Bundesverbands der Pneumologen, Schlaf- und Beatmungsmediziner e. V. (BdP) Correction to: Key summary of German national treatment guidance for hospitalized COVID‑19 patients : Key pharmacologic recommendations from a national German living guideline using an Evidence to Decision Framework (last updated 17.05.2021) Small airway dysfunction as predictor and marker for clinical response to biological therapy in severe eosinophilic asthma: a longitudinal observational study The multi-modal effect of the anti-fibrotic drug pirfenidone on NSCLC Human alveolar epithelial cells type II are capable of TGFβ-dependent epithelial-mesenchymal-transition and collagen-synthesis Human alveolar epithelial cells type II are capable of TGFβ-dependent epithelial-mesenchymal-transition and collagen-synthesis Prognosis and longitudinal changes of physical activity in idiopathic pulmonary fibrosis Der Phosphodiesterase-4-Hemmer-Roflumilast : Fortschritt bei der Therapie der COPD Inhalative Glukokortikoide zur Therapie obstruktiver Ventilationsstörungen

Hinweis

Die Betaversion beinhaltet noch nicht alle Funktionen und Informationen des Katalogs des DNB-Portals. Falls Sie Informationen vermissen oder ein Medium bestellen wollen, besuchen Sie bitte die entsprechende Seite im Katalog des DNB-Portals über folgenden Link:

Katalog der Deutschen Nationalbibliothek

Klaus F. Rabe

Effects of triple therapy on disease burden in patients of GOLD groups C and D: results from the observational COPD cohort COSYCONET

S2k-Leitlinie zur fachärztlichen Diagnostik und Therapie von Asthma 2023 : herausgegeben von der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e. V.

Risk Assessment for Patients with Chronic Respiratory Conditions in the Context of the SARS-CoV-2 Pandemic Statement of the German Respiratory Society with the Support of the German Association of Chest Physicians

Risk Assessment for Patients with Chronic Respiratory Conditions in the Context of the SARS-CoV-2 Pandemic Statement of the German Respiratory Society with the Support of the German Association of Chest Physicians

Correction to: Key summary of German national treatment guidance for hospitalized COVID‑19 patients : Key pharmacologic recommendations from a national German living guideline using an Evidence to Decision Framework (last updated 17.05.2021)

Key summary of German national treatment guidance for hospitalized COVID-19 patients : Key pharmacologic recommendations from a national German living guideline using an Evidence to Decision Framework (last updated 17.05.2021)

Correction to: Key summary of German national treatment guidance for hospitalized COVID‑19 patients : Key pharmacologic recommendations from a national German living guideline using an Evidence to Decision Framework (last updated 17.05.2021)

Small airway dysfunction as predictor and marker for clinical response to biological therapy in severe eosinophilic asthma: a longitudinal observational study

The multi-modal effect of the anti-fibrotic drug pirfenidone on NSCLC

Human alveolar epithelial cells type II are capable of TGFβ-dependent epithelial-mesenchymal-transition and collagen-synthesis

Human alveolar epithelial cells type II are capable of TGFβ-dependent epithelial-mesenchymal-transition and collagen-synthesis

Prognosis and longitudinal changes of physical activity in idiopathic pulmonary fibrosis

Der Phosphodiesterase-4-Hemmer-Roflumilast : Fortschritt bei der Therapie der COPD

Inhalative Glukokortikoide zur Therapie obstruktiver Ventilationsstörungen